Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,540 total articles
Enlight Renewable Energy (ENLT) is a diversified renewables platform with growing project scale in the U.S., Europe and MENA. The stock is best accumulated on pullbacks; our tactical entry at $84 with a $110 target and $72 stop fits a long-term 180 trading day view that captures project IV and operational ramp from large financed assets.
Palantir's business metrics are still impressive — double-digit to triple-digit growth in key lines and healthy margins — yet the stock has corrected sharply from its late-2025 highs. This trade idea proposes a tactical long entry on weakness around $130 with a stop under $118 and a primary target at $170 over a mid-term horizon. The idea hinges on…
Nebius (NBIS) plunged on news that Meta plans to monetize excess AI compute. The sell-off is a sentiment shock, not a confirmed loss of customers. With contracted power capacity north of 4 GW, aggressive 2026 revenue guidance of $3.0-3.4B, and improving cash flow metrics reported in June, Nebius offers a high-risk, high-reward swing entry. Trade pl…
Apple may be preparing a new iPhone pricing tier aimed at expanding volume and services adoption. Given the company's cash generation, large buyback capacity and current technical posture, a disciplined long trade can capture upside from re-rated multiples or stronger-than-feared unit growth while controlling downside risk.
Southwest (LUV) has the operational footprint and recent capital-return actions to accelerate gains if jet fuel stabilizes under $70. The stock trades around $50.75 with a market cap near $24.8B, P/E ~32 and positive technical momentum. This trade idea lays out an entry at $51.00, a stop at $46.00 and a target of $60.00 on a long-term horizon (180 …
Summit Therapeutics (SMMT) is a clinical-stage biotech with a near-term regulatory binary and a market cap around $12.07B. The FDA accepted its BLA for ivonescimab with a PDUFA date of 11/14/2026, and the stock trades well below its 52-week high despite a meaningful short interest. This trade idea outlines a long entry at $15.55, a stop at $12.50 a…
Qualys looks positioned to extend its recent rally. Solid Q2 results, attractive free cash flow of $290.5M and a near-term breakout to a 52-week high suggest a tactical long. Entry, stop and a mid-term target are provided with a clear risk framework.
Aeluma (ALMU) has taken hits after a post-earnings pullback, but recent non-dilutive government awards, a strategic hire from Intel, and a compact float suggest a tradable long with defined risk. This idea frames a mid-term swing entry and layered upside targets while outlining the execution and dilution risks that could derail the thesis.
McDonald's ($MCD) has pulled back from its 2026 peak and is offering an actionable entry while underlying cash flow and dividend durability remain intact. The trade targets a re-rating as operating leverage from digital, menu mix, and price recovery supports margins. Entry at $275, stop at $264.50, target $320 over a mid-term horizon (45 trading da…
Coursera is a pragmatic long idea after the Udemy merger: combined scale, material cost synergies and an AI-native roadmap justify a long-term (180 trading days) trade. The company trades at about $1.69B market cap with an EV of ~$900M, free cash flow of $88.6M, and a P/S near 2.2. Technical indicators show bullish momentum while short interest and…
CVS has quietly become a healthcare-services hybrid: strong cash generation, targeted AI and venture investments, and a diversified revenue mix justify a tactical long. At $104.73 the stock offers asymmetric upside to consensus targets while valuation metrics (EV/EBITDA 13.4, P/S 0.33) keep risk manageable. Trade plan below balances upside to $115 …
Chipotle has been punished for slowing sales and margin compression. The setup today is a mean-reversion trade: valuations imply recovery if same-store sales stabilize and restaurant-level margins recover. I like a mid-term long (45 trading days) that targets $42 while keeping risk defined at $31.
United Therapeutics offers a rare combination in biotech: durable product revenue, strong free cash flow, and fresh clinical catalysts. Against speculative names that trade on preclinical promises, UTHR's balance sheet, buybacks and Phase III wins make it the practical choice for a trade that prioritizes profits over possibility. This plan lays out…
Ascendis has moved from pure R&D to a commercial-stage endocrinology franchise. Positive five-year TransCon PTH data, a new pediatric approval, a Nasdaq ordinary-share listing and share buybacks have set the stage for revenue growth. Technical momentum is strong, and the balance of fundamental catalysts versus execution risk supports an initiating …
Mastercard’s dominant payments network and recurring, high-margin cash flows make it a compelling long trade today. At $539.35 the stock looks expensive on headline multiples, but structural advantages, steady free cash flow ($17.8B) and new product rollouts (Click to Pay, tokenization, stablecoin consortium work) give the company room to grow into…
BE Semiconductor (BESIY) has pulled back from its 52-week high but still sits as a direct beneficiary of rising AI-focused semiconductor packaging and assembly spending. The stock offers an asymmetric mid-term trade: high reward if AI capex holds, but elevated valuation and cyclical downside risk demand a tight stop. Trade plan: enter $295, target …
PVH sold off after a regional slowdown hit guidance. The business still generates strong free cash flow, trades at low multiples, and carries modest leverage. If geopolitical pressures in EMEA ease, PVH offers asymmetric upside from current levels with defined risk controls.
Kyverna's registrational SPS data validated miv-cel's mechanism and cleared the first commercial hurdle. The market still prices the company like a single-indication biotech. With a market cap near $540M, low net leverage, and a deep autoimmune pipeline (gMG, lupus nephritis), KYTX offers a compelling asymmetric risk/reward for an event-driven long…
Victory Capital (VCTR) combines inorganic scale from the Amundi US deal, durable fee-bearing assets across mutual funds, ETFs and institutional channels, plus shareholder returns that support the thesis. At $87.80, the shares trade at ~18.7x earnings with free cash flow of $422M and a market cap near $5.48B. I recommend a tactical long for mid-term…
EquipmentShare is trading near its 52-week low while executing a refinancing and board refresh. The company's T3 initiative (newer connected rental product) increases the optionality of recurring rental revenue. We lay out a mid-term trade: enter $19.00, stop $17.50, target $26.00, horizon 45 trading days.
Nano Labs (NA) is a $40M micro-cap fabless semiconductor firm pivoting into AI hardware and data-center infrastructure. The stock sits near $1.73 with a PE of 1.8 and PB of 0.37, heavy short interest, and a string of product and partnership announcements. I recommend a speculative long as a mid-term trade: entry $1.70, stop $1.20, target $3.50, hor…
Hillman Solutions (HLMN) is trading at an attractive entry after a pullback toward its 52-week low. The business mixes recurring, low-tech distribution with growing robotics/digital offerings and recent acquisitions that add roughly $30M in expected net sales for fiscal 2026. At roughly $1.6B market cap and an EV/EBITDA under 10, a disciplined long…
Micron reported a blowout fiscal quarter with $41.5B revenue, gargantuan margins and multi-year customer agreements that lock in a large share of DRAM and NAND volumes. The stock has run hard; I recommend buying a disciplined pullback to $900 with a $1,500 target and $800 stop — horizon ~180 trading days — because the fundamentals and cash flow pro…
NXP Semiconductors trades at $276.80 but carries fundamentals and forward catalysts that argue for a tactical long into earnings. With a $69B market cap, 2026 free cash flow of ~$2.71B, a reasonable P/E of 26 and accelerating data-center and automotive revenue, the risk/reward favors buying the dip ahead of results. This trade lays out an entry, st…
Centene's business is being re-priced not because healthcare demand vanished but because administrative frictions and subsidy rollbacks have turned membership math volatile. Membership losses, a weak 2026 outlook and stretched valuations after a sharp rally create a tactical short opportunity. The company still generates meaningful free cash flow, …
